Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botox for Prevention of Postoperative Pancreatic Fistula
NCT04965311Phase 2Terminated
- Sponsor
- OHSU Knight Cancer Institute
- Start
- Mar 2023
- Primary completion
- Jul 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of botulinum toxin type A in pancreatic fistula (POPF), sponsored by OHSU Knight Cancer Institute. Primary endpoint: Clinically Relevant Postoperative Pancreatic Fistula at 30 days. Started Mar 2023; status: terminated.
02
Drugs
botulinum toxin type A
03
Conditions
pancreatic fistula (POPF)
Beyond the preview
Go deeper on NCT04965311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04965311.